A carregar...
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity
KXO1 (tirbanibulin or KX2–391) is as a non-ATP-competitive inhibitor of SRC proto-oncogene nonreceptor tyrosine kinase (SRC) and is being clinically investigated for the management of various cancers and actinic keratosis. Recently, KXO1 has also been shown to strongly inhibit tubulin. Interestingly...
Na minha lista:
| Publicado no: | J Biol Chem |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Biochemistry and Molecular Biology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6885616/ https://ncbi.nlm.nih.gov/pubmed/31628188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA119.010732 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|